UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

Discover insights on the challenges of CTCs and ctDNA from liquid biopsies as cancer diagnostic tools, how novel technology is helping to overcome some of these issues and the future monitoring ...

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

DGIST research team led by Yoonhee Lee and Gyogwon Koo enhances lung cancer diagnostic accuracy by combining exosome physical ...

Guardant Health reports strong Q2 2025 results with 31% revenue growth, raised guidance, and momentum in oncology and Shield screening.